How Pharm.D. was paid
$6.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| René Russo, Pharm.D.President and Chief Executive Officer | $643,700 | $128,740 | $5,293,319 | $371,736 | $14,000 | $6,451,495 |
| Christopher FrankenfieldChief Financial and Operating Officer | $533,100 | $106,620 | $2,287,752 | $287,874 | $14,000 | $3,229,346 |
| Katarina Luptakova, M.D.Chief Medical Officer | $481,300 | — | $1,505,578 | $196,370 | $14,000 | $2,197,248 |
What changed and why
- $6.5MRené Russo received total compensation of $6,451,495 for fiscal year 2025, compared to $1,454,729 for the prior year.
- $644KBase salaries increased effective January 1, 2025, bringing Dr. Russo's base salary to $643,700.
- 105%The board determined the company achieved 105% of its corporate goals for the 2025 performance period.
- $129KDiscretionary bonuses of $128,740 and $106,620 were awarded for the AbbVie business development transaction.
- A one-time repricing of certain outstanding employee stock options was approved in November 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.